NF2 and benign meningioma: To examine whether STX3451 or STX2895 affected the viability of human NF2 tumour cells, in a manner similar to those in NF1 tumour cells, we exposed Ben-Men-1(NF2−/− benign meningioma cells), CH157MN (NF2−/− meningioma cells), HEI-193 (NF2−/− benign vestibular Schwannoma cells), KT21 (NF2−/− malignant meningioma cells) and IOMM-Lee (NF2+/+ malignant meningioma cells) to the individual agents or to a combination of the two.